Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In
New User Registration
*Required field
This entry was posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology. Bookmark the permalink.